Pricing...why are they raising the cash...I may be wrong but
the company is telegraphing it.
"Insmed expects to use the proceeds from the sale of the common stock to fund
further clinical development of its lead product candidate, ARIKACE(R), to fund
its efforts to obtain regulatory approvals "
Management imho has been telegraphing what the offering was for.. "additional data for NTM ? of a Phase3 trial for both NTM and CF ...that takes a lot of bucks - easily 35 M each...we shall see.. If NTM hits whatever "encourging "is ?(FDA) - Insmed will do quite well indeed...Good Luck
OT means off topic.What I hoped would be a thread ( in July )) was spammed by 3 IDs by kvncmcdd. This thread is way above our clowns head, so pulllease ! put me on ignore..I find this board so amazingly accurate sentiment indicator.Sentiment is high here...Good Luck
kvncmcdd, now in at two, what a clown The call is about the CF trial,....the price pivot is @.54. My newest ignore.... I was surprised by the timing of this dilution. This is a 30 day event and then the FDA... so far kevie,you never got this company right, but Im pulling for Insmed. surfs up! adios